Skip to main content
Equibles

NRSN · NeuroSense Therapeutics Ltd.

Track NRSN — free

Use NRSN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRSN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.35 +0.02 (+4.58%) At close · Sep 11
Rebalance outlook locked
Market Cap
$12.60M
Shares
37.94M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.35 Open$0.35 Day$0.33–0.35 52W close$0.33–1.27 Avg vol 30d513K Short int469K · 1.2% float · 1.5d Short vol56% DataDec 2021–Sep 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+37.0%
Year over year · more shares
Price change (1Y)
-75.6%
Trailing year
Short interest
1.2%
Latest settlement · 1.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −55%
below
Price vs 50-day avg −34%
below
RSI (14) 38
neutral
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −54%
trailing
YTD return −55%
this year
Relative strength −72%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +2 funds added
Insider flow Accumulating
Net +$400.0K over 90 days · 0% sells
Short interest Falling
1.24% of float · ▼ -4.1% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Squeeze score 42
elevated · 0–100
Fundamentals
Fair
EPS growth +19%
Y/Y
Free cash flow $-7.7M
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −74%
past year
ATR 19.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−55% Bearish
Price vs 50-day avg
−34% Bearish
RSI (14)
38 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +2 funds added
Insider flow Accumulating
Net +$400.0K over 90 days · 0% sells
Short interest Falling
1.24% of float · ▼ -4.1% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 2% Range high $1
vs 200-day avg -55% vs 50-day avg -34%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NRSN
NeuroSense Therapeutics Ltd.
this stock
$12.60M -54.9% — — 1.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
14
% held
1.5%
Net QoQ
+17.6K sh
Top holder
UBS Group AG
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
469.1K
Days to cover
1.5d
Change
-20.0K sh
View
Short Volume
Short vol %
56%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$3
As of
Aug 5, 2026
View
Off-Exchange
Off-exchange %
56.7%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$400.0K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-11.1M
EPS diluted
$-0.44
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 9, 2026
This year
25
View
Exempt Offerings
Offering
$5.0M
Filed
Dec 12, 2024
View

Performance

5D 20D 120D MTD YTD
NRSN -13.6% -21.6% -53.9% -18.6% -54.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -12.4% -19.9% -71.7% -18.3% -66.9%
Key facts CIK 1875091 CUSIP M74240108 13F (30d) 6 filings 6 filers Visit website Investor relations